HORIZON THERAPEUTICS PLC (HZNP) Stock Fundamental Analysis
USA - NASDAQ:HZNP - IE00BQPVQZ61 - Common Stock
116.3 USD
+0.05 (+0.04%)
116.34 USD
+0.04 (+0.03%)
HZNP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. HZNP gets an excellent profitability rating and is at the same time showing great financial health properties. HZNP has a correct valuation and a medium growth rate. These ratings could make HZNP a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
HZNP had positive earnings in the past year.
HZNP had a positive operating cash flow in the past year.
Of the past 5 years HZNP 4 years were profitable.
In the past 5 years HZNP always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.71%, HZNP belongs to the top of the industry, outperforming 95.21% of the companies in the same industry.
The Return On Equity of HZNP (8.25%) is better than 95.38% of its industry peers.
The Return On Invested Capital of HZNP (5.35%) is better than 95.87% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for HZNP is significantly below the industry average of 15.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| ROIC | 5.35% |
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
1.3 Margins
With an excellent Profit Margin value of 12.02%, HZNP belongs to the best of the industry, outperforming 96.04% of the companies in the same industry.
In the last couple of years the Profit Margin of HZNP has declined.
HZNP has a better Operating Margin (15.58%) than 96.53% of its industry peers.
HZNP's Operating Margin has improved in the last couple of years.
HZNP's Gross Margin of 75.21% is amongst the best of the industry. HZNP outperforms 84.49% of its industry peers.
HZNP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.58% | ||
| PM (TTM) | 12.02% | ||
| GM | 75.21% |
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HZNP is destroying value.
Compared to 1 year ago, HZNP has about the same amount of shares outstanding.
HZNP has a better debt/assets ratio than last year.
2.2 Solvency
HZNP has an Altman-Z score of 5.10. This indicates that HZNP is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.10, HZNP belongs to the best of the industry, outperforming 81.35% of the companies in the same industry.
The Debt to FCF ratio of HZNP is 2.67, which is a good value as it means it would take HZNP, 2.67 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.67, HZNP belongs to the best of the industry, outperforming 95.54% of the companies in the same industry.
HZNP has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
HZNP has a Debt to Equity ratio of 0.48. This is in the lower half of the industry: HZNP underperforms 74.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 2.67 | ||
| Altman-Z | 5.1 |
ROIC/WACC0.75
WACC7.16%
2.3 Liquidity
A Current Ratio of 4.27 indicates that HZNP has no problem at all paying its short term obligations.
HZNP has a Current ratio (4.27) which is in line with its industry peers.
HZNP has a Quick Ratio of 4.09. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of HZNP (4.09) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.27 | ||
| Quick Ratio | 4.09 |
3. Growth
3.1 Past
HZNP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.39%.
The Earnings Per Share has been growing by 33.01% on average over the past years. This is a very strong growth
Looking at the last year, HZNP shows a decrease in Revenue. The Revenue has decreased by -4.42% in the last year.
Measured over the past years, HZNP shows a very strong growth in Revenue. The Revenue has been growing by 28.00% on average per year.
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
3.2 Future
Based on estimates for the next years, HZNP will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.92% on average per year.
The Revenue is expected to grow by 9.94% on average over the next years. This is quite good.
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 25.90, the valuation of HZNP can be described as expensive.
HZNP's Price/Earnings ratio is rather cheap when compared to the industry. HZNP is cheaper than 95.54% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.89. HZNP is around the same levels.
A Price/Forward Earnings ratio of 20.14 indicates a rather expensive valuation of HZNP.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HZNP indicates a rather cheap valuation: HZNP is cheaper than 96.53% of the companies listed in the same industry.
HZNP is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.9 | ||
| Fwd PE | 20.14 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HZNP is valued cheaply inside the industry as 94.88% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HZNP indicates a rather cheap valuation: HZNP is cheaper than 96.37% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.79 | ||
| EV/EBITDA | 27.94 |
4.3 Compensation for Growth
The excellent profitability rating of HZNP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2Y8.89%
EPS Next 3Y11.9%
5. Dividend
5.1 Amount
No dividends for HZNP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
116.3
+0.05 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap26.63B
Revenue(TTM)3.64B
Net Income(TTM)438.00M
Analysts50.91
Price Target118.83 (2.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.7%
Min EPS beat(2)-27.35%
Max EPS beat(2)13.95%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-27.35%
Max EPS beat(4)21.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.41%
Min Revenue beat(2)-9.59%
Max Revenue beat(2)6.77%
Revenue beat(4)3
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-9.59%
Max Revenue beat(4)6.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.9 | ||
| Fwd PE | 20.14 | ||
| P/S | 7.31 | ||
| P/FCF | 27.79 | ||
| P/OCF | 25.59 | ||
| P/B | 5.01 | ||
| P/tB | 26.53 | ||
| EV/EBITDA | 27.94 |
EPS(TTM)4.49
EY3.86%
EPS(NY)5.77
Fwd EY4.97%
FCF(TTM)4.19
FCFY3.6%
OCF(TTM)4.54
OCFY3.91%
SpS15.92
BVpS23.19
TBVpS4.38
PEG (NY)N/A
PEG (5Y)0.78
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| ROCE | 6.77% | ||
| ROIC | 5.35% | ||
| ROICexc | 7.58% | ||
| ROICexgc | 27.86% | ||
| OM | 15.58% | ||
| PM (TTM) | 12.02% | ||
| GM | 75.21% | ||
| FCFM | 26.3% |
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
ROICexc(3y)9.75%
ROICexc(5y)6.96%
ROICexgc(3y)39.54%
ROICexgc(5y)N/A
ROCE(3y)8.46%
ROCE(5y)6.07%
ROICexgc growth 3Y27.62%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.99%
ROICexc growth 5YN/A
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 2.67 | ||
| Debt/EBITDA | 2.66 | ||
| Cap/Depr | 21.15% | ||
| Cap/Sales | 2.26% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 108.78% | ||
| Profit Quality | 218.81% | ||
| Current Ratio | 4.27 | ||
| Quick Ratio | 4.09 | ||
| Altman-Z | 5.1 |
F-Score6
WACC7.16%
ROIC/WACC0.75
Cap/Depr(3y)32.95%
Cap/Depr(5y)21.63%
Cap/Sales(3y)3.95%
Cap/Sales(5y)2.73%
Profit Quality(3y)169.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
EBIT growth 1Y-37.19%
EBIT growth 3Y74.4%
EBIT growth 5YN/A
EBIT Next Year6.03%
EBIT Next 3Y14.62%
EBIT Next 5Y17.3%
FCF growth 1Y83.52%
FCF growth 3Y42.98%
FCF growth 5Y33.65%
OCF growth 1Y72.19%
OCF growth 3Y43.43%
OCF growth 5Y34.64%
HORIZON THERAPEUTICS PLC / HZNP FAQ
What is the fundamental rating for HZNP stock?
ChartMill assigns a fundamental rating of 6 / 10 to HZNP.
What is the valuation status of HORIZON THERAPEUTICS PLC (HZNP) stock?
ChartMill assigns a valuation rating of 5 / 10 to HORIZON THERAPEUTICS PLC (HZNP). This can be considered as Fairly Valued.
How profitable is HORIZON THERAPEUTICS PLC (HZNP) stock?
HORIZON THERAPEUTICS PLC (HZNP) has a profitability rating of 8 / 10.
Can you provide the financial health for HZNP stock?
The financial health rating of HORIZON THERAPEUTICS PLC (HZNP) is 7 / 10.